78,485 results match your criteria Acute Myeloid Leukemia Not Otherwise Categorized


Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndrome.

Cancer Genet 2020 Jun 14;245:42-48. Epub 2020 Jun 14.

Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Abramson Research Center, Room 716D, 3615 Civic Center Blvd., Philadelphia, PA 19104, United States; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States. Electronic address:

Gain of function variants in SAMD9 cause MIRAGE syndrome, a rare Mendelian disorder that results in myeloid dysplastic syndrome (MDS), poor immune response, restricted growth, adrenal insufficiency, ambiguous genitalia, feeding difficulties and most often significantly reduced lifespan. In this study, we describe histomorphologic and genetic changes occurring in serial bone marrow measurements in a patient with MIRAGE syndrome and untreated MDS of 9 years. Histomorphological analysis during childhood showed progressive hypocellularity with erythroid and megakaryocytic dysplasia and cytogenetic testing demonstrated monosomy 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2020.06.002DOI Listing

Loss of TET2 Affects Proliferation and Drug Sensitivity through Altered Dynamics of Cell-State Transitions.

Cell Syst 2020 Jun 24. Epub 2020 Jun 24.

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

A persistent puzzle in cancer biology is how mutations, which neither alter growth signaling pathways nor directly interfere with drug mechanism, can still recur and persist in tumors. One example is the mutation of the DNA demethylase tet methylcytosine dioxygenase 2 (TET2) in acute myeloid leukemias (AMLs) that frequently persists from diagnosis through remission and relapse, but whose fitness advantage in chemotherapy is unclear. Here, we use isogenic human AML cell lines to show that TET2 loss of function alters the dynamics of transitions between differentiated and stem-like states. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cels.2020.06.003DOI Listing

Rubbing Out Leukemia Stem Cells by Erasing the Eraser.

Cell Stem Cell 2020 Jul;27(1):3-5

Molecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address:

In this issue of Cell Stem Cell, Shen et al. (2020) and Wang et al. (2020) independently identify the essential function of mA demethylase ALKBH5 in maintaining myeloid leukemia stem cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2020.06.009DOI Listing

Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study.

Cancer Sci 2020 Jul 3. Epub 2020 Jul 3.

Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Although next-generation sequencing-based panel testing is well-practiced in the field of cancer medicine for the identification of target molecules in solid tumors, the clinical utility and clinical issues surrounding panel testing in hematological malignancies have yet to be fully evaluated. We conducted a multicenter prospective clinical-sequencing study to verify the feasibility of a panel test for hematological tumors, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. Out of 96 eligible patients, 79 patients (82%) showed potentially actionable findings, based on the clinical-sequencing assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14552DOI Listing

Inherited Thrombocytopenia Caused by Germline Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome.

J Investig Med High Impact Case Rep 2020 Jan-Dec;8:2324709620938941

Hematology-Oncology Leukemia Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

Thrombocytopenia 2 (THC2) is an autosomal dominant disorder characterized by ankyrin repeat domain 26 mutation and moderate thrombocytopenia. THC2 exposes patients to a low risk of bleeding and an increased likelihood of myelodysplastic syndrome/acute myeloid leukemia. Germline evaluation for a genetic disorder should be considered when a patient presents with isolated thrombocytopenia and associated dysmegakaryopoiesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709620938941DOI Listing

Depleting interferon regulatory factor-1(IRF-1) with CRISPR/Cas9 attenuates inducible oxidative metabolism without affecting RA-induced differentiation in HL-60 human AML cells.

FASEB Bioadv 2020 Jun 22;2(6):354-364. Epub 2020 May 22.

Department of Biomedical Sciences Cornell University Ithaca NY USA.

The known collaboration between all-transretinoic acid and interferon motivates this study of the dependence of RA-induced leukemic cell differentiation on interferon regulatory factor-1 (IRF-1), a transcription factor that is the main mediator of interferon effects. In the HL-60 acute myeloid leukemia (AML) model that represents a rare RA-responsive subtype of AML, IRF-1 is not expressed until RA induces its prominent expression, and ectopic IRF-1 expression enhances RA-induced differentiation, motivating interest in how IRF-1 is putatively needed for RA response. Accordingly, we created CRISPR/Cas9-mediated IRF-1 knockout HL-60 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fba.2020-00004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325585PMC

Identification the prognostic value of glutathione peroxidases expression levels in acute myeloid leukemia.

Ann Transl Med 2020 Jun;8(11):678

Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Background: Glutathione peroxidases (GPXs) are an enzyme family with peroxidase activity. Abnormal GPX expression is associated with carcinogenesis. However, the potential role of the GPX gene family in acute myeloid leukemia (AML) remains to be comprehensively examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm-20-3296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327321PMC

Bone marrow metastasis of glioblastoma multiforme mimicking acute myeloid leukemia.

Oxf Med Case Reports 2020 Jun 25;2020(6):omaa040. Epub 2020 Jun 25.

Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

A 46-year-old female patient with glioblastoma multiforme (GBM), IDH wild type developed severe pancytopenia 5 months after postoperative chemoradiotherapy. Bone marrow aspirate showed normocellular marrow with 70.0% abnormal cells, which suggested the possibility of acute myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/omcr/omaa040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315933PMC

CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity.

Haematologica 2020 Jul 2. Epub 2020 Jul 2.

3rd Medical Department, SCRI-LIMCR, Paracelsus Medical University, Cancer Cluster Salzburg;

Adhesive properties of leukemia cells shape the degree of organ infiltration and the extent of leukocytosis. CD44 and the integrin VLA-4, a CD49d/CD29 heterodimer, are important factors of progenitor cell adhesion in bone marrow (BM). Here, we report their cooperation in acute myeloid leukemia (AML) by a novel non-classical CD44-mediated way of inside-out VLA-4 activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.231944DOI Listing

Expression and clinical significance of phospholipase D1 in acute myeloid leukemia.

Hematology 2020 Dec;25(1):270-275

Department of Pathology, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, People's Republic of China.

Phospholipase D (PLD) is known to participate in several aspects of cellular processes including cell mitosis, migration, phagocytosis, and membrane vesicle trafficking. The role of PLD has been investigated in multiple cancers except hematologic malignances. We enrolled 291 patients with acute myeloid leukemia (AML) and detected PLD1 mRNA expression levels of their bone marrow samples by quantitative real-time PCR (qRT-PCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2020.1786971DOI Listing
December 2020

[Hepatolienal candidosis as a rare differential diagnosis of disseminated small parenchym lesions].

Dtsch Med Wochenschr 2020 Jul 2;145(13):912-916. Epub 2020 Jul 2.

Klinik für Diagnostische und Interventionelle Radiologie, Uniklinikum Ulm, Ulm.

History:  We report about a 17-year-old patient with the secondary malignancy of acute myeloid leukemia (AML). He developed fever of unclear origin during the hematopoietic stem cell transplantation.History We report about a 17-year-old patient with the secondary malignancy of acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1164-0043DOI Listing

Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro.

Blood Adv 2020 Jul;4(13):3000-3010

Department of Hematology, University Hospital Essen, Essen, Germany.

Acute myeloid leukemia (AML) is characterized by a high relapse rate and dismal long-term overall survival which is related to persistence of leukemia-initiating cells in their niche. Different animal models of myeloid malignancies reveal how neoplastic cells alter the structural and functional characteristics of the hematopoietic stem cell niche to reinforce malignancy. Understanding and disruption of the microenvironmental interactions with AML cells are a vital need. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001292DOI Listing

The expression and regulation of HOX genes and membrane proteins among different cytogenetic groups of acute myeloid leukemia.

Mol Genet Genomic Med 2020 Jul 2:e1365. Epub 2020 Jul 2.

Hubei Bioinformatics & Molecular Imaging Key Laboratory, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.

Background: The cytogenetic aberrations were considered as markers for diagnosis and prognosis in acute myeloid leukemia (AML), while the expression and regulation under different cytogenetic groups remain to be fully elucidated.

Methods: In this paper, for favorable, poor, and cytogenetically normal groups of AML patients, we performed comprehensive bioinformatics analyses including identifying differentially expressed genes (DEGs) and microRNAs (miRNAs) among them, functional enrichment and regulatory networks.

Results: We found that DEGs were enriched in membrane-related processes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mgg3.1365DOI Listing

First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.

Leuk Res Rep 2020 18;14:100213. Epub 2020 Jun 18.

University Hospitals Birmingham NHS Foundation Trust, Heartlands Hospital.

Herein we present a female patient aged 61 with Philadelphia negative acute lymphoblastic leukaemia demonstrating near haploid karyotype and abnormal TP53 expression at diagnosis, who relapsed with lineage switch as Acute Monocytic Leukemia post allogeneic stem cell transplantation. Molecular analysis established that both neoplasms were derived from the same founder clone. The leukemic lineage switch phenomenon has recently re-attracted interest as mechanism of leukemic evasion post treatment with chimeric antigen receptor T-cells but there is paucity of data on its presence post allograft or following novel antibody treatments such as Inotuzumab Ozogamicin or Blinatumomab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lrr.2020.100213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317226PMC

Dendrogenin A synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo.

Cancers (Basel) 2020 Jun 29;12(7). Epub 2020 Jun 29.

Unité Mixte de Recherche (UMR)1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France.

Dendrogenin A (DDA) is a mammalian cholesterol metabolite that displays potent antitumor properties on acute myeloid leukemia (AML). DDA triggers lethal autophagy in cancer cells through a biased activation of the oxysterol receptor LXRβ, and the inhibition of a sterol isomerase. We hypothesize that DDA could potentiate the activity of an anticancer drug acting through a different molecular mechanism, and conducted in vitro and in vivo combination tests on AML cell lines and patient primary tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071725DOI Listing

Vitamin B6 Fuels Acute Myeloid Leukemia Growth.

Authors:
Shuai Jiang

Trends Cancer 2020 Jul 2;6(7):536-537. Epub 2020 Apr 2.

Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA. Electronic address:

Mounting evidence indicates that vitamins C and D are linked to tumor growth, but the relevance of vitamin B6 remains uncertain. In a recent study, Chen et al. demonstrate that pyridoxal kinase promotes vitamin B6 phosphorylation, producing the active form pyridoxal 5'-phosphate, which regulates two key metabolic enzymes required for acute myeloid leukemia (AML) cell growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2020.03.005DOI Listing

NPM1-mutated acute myeloid leukemia: from bench to bedside.

Blood 2020 Jul 1. Epub 2020 Jul 1.

Hematology, CREO, University of Perugia, Perugia, Italy.

The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations represent the most common genetic lesion in adult AML (about one-third of cases) and act deterministically to cause the aberrant cytoplasmic delocalization of NPM1 mutants. Because of its unique features, NPM1-mutated AML is recognized as a distinct entity in the 2016 World Health Organization classification of hematopoietic neoplasms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004226DOI Listing

Screening for Dental Infections Achieves 6-Fold Reduction in Dental Emergencies During Induction Chemotherapy for Acute Myeloid Leukemia.

JCO Oncol Pract 2020 Jul 1:OP2000107. Epub 2020 Jul 1.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Purpose: Patients with newly diagnosed acute myeloid leukemia (AML) are at risk of infection, including odontogenic infections, during induction chemotherapy. It is unknown whether clinical dental screening to diagnose and treat odontogenic disease in these patients can reduce the incidence of dental emergencies.

Methods: Between November 1, 2014, and December 31, 2016, we screened 147 patients with newly diagnosed AML before their admission for induction chemotherapy (n 147, "screened" group). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/OP.20.00107DOI Listing

Long non-coding RNA LINC01268 promotes cell growth and inhibits cell apoptosis by modulating miR-217/SOS1 axis in acute myeloid leukemia.

Braz J Med Biol Res 2020 26;53(8):e9299. Epub 2020 Jun 26.

Department of Hematology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.

The aim of this study was to evaluate the pathogenic role of newly identified long non-coding (lnc)-RNA LINCO1268 in acute myeloid leukemia (AML), and investigate its therapeutic potential. The expression level of LINC01268 in AML was measured by quantitative PCR (qPCR). The viability, cell cycle progression, and apoptosis of AML cells were measured by CCK-8 assay and flow cytometry, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1414-431X20209299DOI Listing

Poor Prognosis Biomolecular Factors Are Highly Frequent in Childhood Acute Leukemias From Oaxaca, Mexico.

Technol Cancer Res Treat 2020 Jan-Dec;19:1533033820928436

Laboratorio Juárez, Medicina de Laboratorio Clínico de Alta Especialidad, Biología Molecular e Investigación Clínica, Oaxaca de Juárez, Oaxaca, México.

Objective: To investigate the cellular and molecular epidemiology of acute leukemias in vulnerable populations of children and adolescents in Oaxaca de Juarez, Mexico.

Material And Methods: Descriptive, cross-sectional and retrospective study, conducted from 2014 to 2018 in which profiles of molecular and immunophenotypic aberrations were investigated in children and adolescents diagnosed with acute leukemia, by evaluating 28 molecular abnormalities by HemaVision-Q28 multiplex RT-PCR kit and standardized EuroFlow Immunophenotyping of bone marrow cells.

Results: We included 218 patients, with 82. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1533033820928436DOI Listing

Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia.

Small 2020 Jun 30:e2001890. Epub 2020 Jun 30.

Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China.

Acute myeloid leukemia (AML) is the most common adult acute leukemia with very low survival rate due to drug resistance and high relapse rate. The C-X-C chemokine receptor 4 (CXCR4) is highly expressed by AML cells, actively mediating chemoresistance and reoccurrence. Herein, a chemically synthesized CXCR4 antagonistic peptide E5 is fabricated to micelle formulation (M-E5) and applied to refractory AML mice, and its therapeutic effects and pharmacokinetics are investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/smll.202001890DOI Listing

Extramedullary Gastric Relapse of Acute Myeloid Leukemia After Allogenic Hematopoietic Stem Cell Transplantation.

ACG Case Rep J 2020 May 5;7(5):e00376. Epub 2020 May 5.

Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/crj.0000000000000376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289279PMC

A Review on the Impact of Body Mass Index on Outcomes in Pediatric Leukemia.

J Blood Med 2020 18;11:205-212. Epub 2020 Jun 18.

Department of Hematology and Stem Cell Transplantation, Saint Antoine Hospital, AP-HP, Paris, France.

In the last decades, adults and pediatric obesity have become a major issue in developed countries. Considerable research has been conducted in patients with acute lymphoblastic (ALL) and myeloid leukemia (AML) with the aim of correlating body mass index (BMI) and outcomes in patients undergoing chemotherapy for hematological diseases. In adults, a high BMI has been associated with increased leukemia-related mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JBM.S232655DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308124PMC

Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.

Drug Des Devel Ther 2020 18;14:2413-2422. Epub 2020 Jun 18.

Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, People's Republic of China.

Purpose: Acute myeloid leukemia (AML) is a complex malignancy characterized by the clonal expansion of immature myeloid precursors. The standard treatment for newly diagnosed AML is chemotherapy consisting of cytosine arabinoside (Ara-C) and anthracyclines with disappointing clinical outcomes and severe adverse effects, such as symptomatic bradycardia, neurotoxicity. Thus, it is promising to treat AML through combination drug therapy to reduce the adverse effects of chemotherapeutics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S244648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308242PMC

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.

Bone Marrow Transplant 2020 Jun 30. Epub 2020 Jun 30.

Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.

Myeloid sarcoma (MS) as a solid extra-medullary (EM) manifestation of acute myeloid leukemia (AML), myeloproliferative or myelodysplastic syndromes is a rare presentation of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). The databases of the Departments of Hematology and Oncology of the University Hospitals of Jena and Rostock were screened for patients aged 18 years or older for onset of MS after HSCT for myeloid malignancies between 2002 and 2019. Nineteen patients with MS were identified, the majority of whom had received reduced-intensity conditioning (RIC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0984-4DOI Listing

B-cell maturation antigen expression across hematologic cancers: a systematic literature review.

Blood Cancer J 2020 Jun 30;10(6):73. Epub 2020 Jun 30.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0337-yDOI Listing

HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia.

Cell Death Dis 2020 Jun 30;11(6):492. Epub 2020 Jun 30.

Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Heparan sulfate proteoglycan 2 (HSPG2), also known as perlecan, is a large multi-domain extracellular matrix proteoglycan, which contributes to the invasion, metastasis and angiogenesis of solid tumor. However, very little is known about the effect of HSPG2 on acute myeloid leukemia (AML). This study aims to investigate the prognostic value of the HSPG2 gene in terms of overall survival and leukemia-free survival in patients with AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-020-2694-7DOI Listing

Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2/Akt/mTOR signaling.

Cancer Res 2020 Jun 30. Epub 2020 Jun 30.

Department of Internal Medicine 5 Hematology and Oncology, University of Erlangen

Acute myeloid leukemia (AML) represents the most common acute leukemia amongst adults. Despite recent progress in diagnosis and treatment, long-term outcome remains unsatisfactory. The success of allogeneic stem cell transplantation underscores the immunoresponsive nature of AML creating the basis for further exploiting immunotherapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-20-0024DOI Listing

Crucial Functions of the JMJD1/KDM3 Epigenetic Regulators in Cancer.

Mol Cancer Res 2020 Jun 30. Epub 2020 Jun 30.

Cell Biology, University of Oklahoma Health Sciences Center

Epigenetic changes are one underlying cause for cancer development and often due to dysregulation of enzymes modifying DNA or histones. Most Jumonji C domain-containing (JMJD) proteins are histone lysine demethylases (KDMs) and therefore epigenetic regulators. One JMJD subfamily consists of JMJD1A/KDM3A, JMJD1B/KDM3B and JMJD1C/KDM3C that are roughly 50% identical at the amino acid level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-20-0404DOI Listing

The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: a systematic review and meta-analysis.

Leuk Lymphoma 2020 Jul 1:1-10. Epub 2020 Jul 1.

Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Increasing evidence has revealed that plasma fibrinogen levels may serve as prognostic indicators in patients with acute myeloid leukemia (AML), yet the exact association is still elusive. We conducted a systematic review and meta-analysis of all available studies concerning the relationship between plasma fibrinogen level and survival in AML patients. The pooled hazard ratio (HR) and 95% confidence intervals (CIs) for overall survival (OS) were calculated to evaluate the effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1780587DOI Listing

Immunotherapy in Myeloproliferative Diseases.

Cells 2020 Jun 26;9(6). Epub 2020 Jun 26.

Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

Myeloproliferative diseases, including myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS), are driven by genetic abnormalities and increased inflammatory signaling and are at high risk to transform into acute myeloid leukemia (AML). Myeloid-derived suppressor cells were reported to enhance leukemia immune escape by suppressing an effective anti-tumor immune response. MPNs are a potentially immunogenic disease as shown by their response to interferon-α treatment and allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9061559DOI Listing

Clinicoepidemiological Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India.

J Pediatr Hematol Oncol 2020 Jun 26. Epub 2020 Jun 26.

Departments of Pediatric Oncology.

Introduction: Mixed-phenotype acute leukemia (MPAL) accounts for 1.2% to 5% of acute leukemia across age groups with intermediate prognosis. We evaluated clinicoepidemiological profiles and outcomes of MPAL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001880DOI Listing

Zinc finger and BTB domain-containing protein 46 is essential for survival and proliferation of acute myeloid leukemia cell line but dispensable for normal hematopoiesis.

Chin Med J (Engl) 2020 Jun 26. Epub 2020 Jun 26.

Department of Hematology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.

Background: Zinc finger and BTB domain-containing protein 46 (Zbtb46) is a transcription factor identified in classical dendritic cells, and maintains dendritic cell quiescence in a steady state. Zbtb46 has been reported to be a negative indicator of acute myeloid leukemia (AML). We found that Zbtb46 was expressed at a relatively higher level in hematopoietic stem and progenitor cells (HSPCs) compared to mature cells, and higher in AML cells compared to normal bone marrow (BM) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000000878DOI Listing

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.

Acta Haematol 2020 Jun 30:1-8. Epub 2020 Jun 30.

Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Acute myeloid leukemia (AML) patients not in remission and beyond first or second complete remission are considered allogeneic stem cell transplant (SCT) candidates. We present 361 patients who underwent SCT from matched related or unrelated donors between 2005 and 2013. The purpose was to identify a subgroup of patients with active disease at the time of transplant that benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507012DOI Listing

In Vitro Evolution Reveals a Single Mutation as Sole Source of Src-family Kinase C-helix-out Inhibitor Resistance.

ACS Chem Biol 2020 Jun 30. Epub 2020 Jun 30.

Understanding cancer cell drug resistance to protein-tyrosine kinase inhibitors, which often arises from acquired mutations in the target kinase, is central to the development of more durable therapies. Experimental systems that reveal potential paths to resistance for a given inhibitor and kinase target have an important role in preclinical development of kinase inhibitor drugs. Here we employed a codon mutagenesis strategy to define the mu-tational landscape of acquired resistance in HCK, a member of the SRC tyrosine kinase family and therapeutic target in acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschembio.0c00373DOI Listing

Peculiarities of abnormal karyotypes formation in therapy-related acute leukemias.

Exp Oncol 2020 06;42(2):126-129

Institute of Molecular Biology & Genetics of NAS of Ukraine, Kyiv 03680, Ukraine.

Aim: To determine ways of formation of abnormal karyotypes in two clinical cases of secondary acute leukemias of myeloid and lymphoid lineages.

Material And Methods: Bone marrow cells of one patient with therapy-related acute monoblastic/monocytic leukemia and one patient with therapy-related acute lymphoblastic leukemia were examined by cytogenetic GTG banding technique.

Results: An unusually large number of quantitative and structural anomalies of chromosomes in therapy-related acute monoblastic/monocytic leukemia have been established, which have many features in common with chromothripsis, namely instability of clones that manifested itself through quantitative anomalies (trisomy, monosomy, marker chromosomes, including chromosome 5), structural - t(9;11), deletions of the long arm of chromosomes 8 and 14, derivatives of chromosomes 3 and 7, ring chromosomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14593DOI Listing

Venetoclax with Azacitidine for Two Younger Jehovah's Witness Patients with High Risk Acute Myeloid Leukemia.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Department of Medicine, Division of Hematology, University of Colorado School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25916DOI Listing

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.

Am J Hematol 2020 Jun 29. Epub 2020 Jun 29.

Division of Hematology, Medical University of Graz, Graz, Austria.

Persistent measurable residual disease (MRD) is an increasingly important prognostic marker in acute myeloid leukemia (AML). Currently, MRD is determined by multi-parameter flow cytometry (MFC) or PCR-based methods detecting leukemia-specific fusion transcripts and mutations. However, while MFC is highly operator-dependent and difficult to standardize, PCR-based methods are only available for a minority of AML patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25918DOI Listing

Treatment of Relapsed Acute Myeloid Leukemia.

Curr Treat Options Oncol 2020 Jun 29;21(8):66. Epub 2020 Jun 29.

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Opinion Statement: Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40-50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse (early versus late) and the possibility of allogeneic hematopoietic stem cell transplantation (HSCT). At the time of relapse, we again perform a mutational screening and cytogenetic analysis in all AML patients as clonal evolution of disease is frequent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-020-00765-5DOI Listing

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.

Nat Med 2020 Jun 29. Epub 2020 Jun 29.

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Acute myeloid leukemia (AML) is driven by leukemia stem cells (LSCs) that resist conventional chemotherapy and are the major cause of relapse. Hypomethylating agents (HMAs) are the standard of care in the treatment of older or unfit patients with AML, but responses are modest and not durable. Here we demonstrate that LSCs upregulate the tumor necrosis factor family ligand CD70 in response to HMA treatment resulting in increased CD70/CD27 signaling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-020-0910-8DOI Listing

Simultaneous detection of cluster of differentiation markers on leukemia-derived exosomes by multiplex immuno-polymerase chain reaction via capillary electrophoresis analysis.

Anal Chem 2020 Jun 29. Epub 2020 Jun 29.

Acute myeloid leukemia (AML) is a heterogeneous disease, and there are critical interests in detecting multiple biomarkers as a single biomarker detection cannot reflect the exact phase of the disease. Exosomes derived from different types of AML cells contain respective combinations of cluster of differentiation (CD) that may be used to guide the molecular typing of AML in clinic. Here, aiming to build more precise molecular typing of AML, we demonstrate multiplex immuno-PCR (mI-PCR) assay for simultaneous detection of multiple surface CDs of exosomes of AML via capillary electrophoresis with laser induced fluorescence (CE-LIF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.analchem.0c01464DOI Listing
June 2020
5.636 Impact Factor

MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus.

Blood 2020 Jun 29. Epub 2020 Jun 29.

BC Cancer Agency, Vancouver, British Columbia, Canada.

Hematopoietic clones with leukemogenic mutations arise in healthy people as they age, but progression to acute myeloid leukemia (AML) is rare. Recent evidence suggests that the microenvironment may play an important role in modulating human AML population dynamics. To investigate this concept further, we examined the combined and separate effects of an oncogene (c-MYC) and exposure to IL3, GM-CSF and SCF on the experimental genesis of a human AML in xenografted immunodeficient mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2020006374DOI Listing

Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.

Drug Resist Updat 2020 May 18;52:100703. Epub 2020 May 18.

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China; Graduate School, Chinese Academy of Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P.R. China; Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, P.R. China. Electronic address:

Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy with complex heterogenous genetic and biological nature. Thus, prognostic prediction and targeted therapies might contribute to better chemotherapeutic response. However, the emergence of multidrug resistance (MDR) markedly impedes chemotherapeutic efficacy and dictates poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2020.100703DOI Listing

[Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation].

Ter Arkh 2019 Aug 15;91(8):93-97. Epub 2019 Aug 15.

National Research Center for Hematology.

Sorafenib has been used in acute myeloid leukemias with FLT3-ITD mutation improving the outcomes. However the high incidence of treatment - emergent adverse event may be associated with treatment using sorafenib with cytotoxic chemotherapy. We have reported a case of severe thyroiditis in patient with a relapse of acute myelomonocytic leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.08.000381DOI Listing

[Role of the intensive care in treatment of patients with acute myeloid leukemia].

Ter Arkh 2019 Jul 15;91(7):14-24. Epub 2019 Jul 15.

National Research Center for Hematology.

Aim: Remission induction can be associate, with the life threatening complications and transfer to ICU of de novo acute myeloid leukemia (AML) patients (pts). We evaluate influence of transfer to ICU and life threatening complication on early mortality and long - tram survival of de novo AML pts.

Materials And Methods: Retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000321DOI Listing

[Russian multicenter clinical trials in acute leukemias].

Ter Arkh 2019 Jul 15;91(7):4-13. Epub 2019 Jul 15.

National Research Center for Hematology.

The paper describes the results of 15 consecutive Russian clinical trials in the treatment of different types of acute leukemias, conducted by Russian cooperative group within the last 27-years and included more than 25 hundred patients. It was shown that the 5-years overall survival in AML younger than 60 years patients improved from 20 to 33%, in ALL - from 38 to 65%, in APL - from 0 to 95%. The cooperative work resulted in balanced clinical recommendations and protocols, reproducible in regional hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000325DOI Listing

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.

J Clin Pharmacol 2020 Jun 29. Epub 2020 Jun 29.

Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.

Quizartinib is an FMS-like tyrosine kinase 3 (FLT3) inhibitor that has shown robust clinical activity in patients with FLT3-internal tandem duplication-mutated relapsed/refractory acute myeloid leukemia (AML). This analysis evaluated the population pharmacokinetics (PK) of quizartinib and its active metabolite, AC886, in a pooled analysis of data from 649 healthy volunteers or patients with AML from 8 clinical trials including the phase 3 QuANTUM-R study. Quizartinib was given as a single dose or multiple once-daily doses of 20, 30, 60, or 90 mg. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1680DOI Listing

Expression and prognosis analysis of family in acute myeloid leukemia.

Aging (Albany NY) 2020 Jun 26;12. Epub 2020 Jun 26.

Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, JiangsuPeople's Republic of China.

DNA methyltransferases () by regulating DNA methylation play crucial roles in the progression of hematologic malignancies, especially for acute myeloid leukemia (AML). Accumulating investigations have identified the high incidence of mutation in AML, and it is correlated with poor prognosis. Although a few studies have shown the expression of and their clinical significance in AML, the results remain to be discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.103520DOI Listing

Dying during Covid-19.

Authors:
Bryanna Moore

Hastings Cent Rep 2020 May;50(3):13-15

I had been on the phone with Madeleine's mother for fifteen minutes, and she had sobbed throughout. She pleaded with me, "You won't even let our family visit her together. If you really want to help my daughter, you will let us stay with her. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hast.1122DOI Listing

Serological Evaluation of Anti- Antibodies in Patients with Acute Leukemia and Lymphoma through Chemotherapy.

Iran J Parasitol 2020 Apr-Jun;15(2):187-195

Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Background: is a protozoan parasite that belongs to the family Coccidae. We aimed to evaluate IgG avidity and the changes of anti- immunoglobulins M (IgM) and G (IgG) in patients with acute leukemia and lymphoma.

Methods: Ninety eight patients with Acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and lymphoma, selected from patients referring to Imam Reza Hospital of Tabriz (38°04'N 46°18'E), in terms of the presence of anti- IgM, IgG, IgG avidity antibodies and the major risk factors were evaluated. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311818PMC